LITS Stock — Lite Strategy Inc.: Cash, EV, Pipeline

What they do

Lite Strategy, Inc. (Nasdaq: LITS) is a pharmaceutical company that has historically developed novel and differentiated cancer therapies. During fiscal year 2026, we commenced pre-clinical development programs in nononcologic disease indications. We also hold Litecoin (LTC) tokens as a primary reserve asset as part of our broader institutional treasury initiative.

Source: 10-K FY2026 via SEC EDGAR

Share price

$1.02

Market cap

$31.5M

Cash

$4.3M

Enterprise value

$27.2M

Balance sheet

Cash	$4.3M
Debt	$0.0M
Net cash	$4.3M
Enterprise value	$27.2M
Basic shares	29.9M shares
Fully diluted shares	34.0M shares
Fully diluted market cap	$34.7M
Cash per share	$0.14
Quarterly burn	$1.2M
Cash runway	4.9 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

30.4M

Pre-funded warrants

0.5M

Options

—

RSUs

—

Warrants

3.1M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

34.0M

Cap table as of 2026-09-22.

Price history

Loading LITS daily closes…

Loading price history…

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

Voruciclib

Preclinical · Active Modality: oral selective CDK9 inhibitor

Target CDK9

Partnerships Presage (exclusive worldwide license)

Indications

non-oncology indications (preclinical) (Preclinical)

Status note All oncology clinical development discontinued; clinical trial activities ceased September 2024; preclinical work in non-oncology indications commenced Q2 FY2026.

Zandelisib

Phase 2 · Terminated Modality: oral selective PI3K-delta inhibitor

Target PI3K-delta

Partnerships Kyowa Kirin (license terminated 2023)

Indications

indolent B-cell lymphomas (Phase 2)

Status note Development discontinued November 2022 after FDA feedback on Phase 3 COASTAL design; assessing out-licensing or sale opportunities.

Per-asset detail extracted from the 10-Q filed 2026-05-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	67,292	no change	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

LITS — Lite Strategy Inc. ☆